Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Bolivia Orders Pre-Trial Detention of Former President Luis Arce Over Embezzlement Probe 
Japan Weighs New Tax Breaks to Boost Corporate Investment Amid Spending Debate 
Bolsonaro’s Defense Requests Hospital Transfer and Humanitarian House Arrest 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 
Tunisia Protests Grow as Opposition Unites Against President Kais Saied’s Rule 
Supreme Court to Review Legality of Trump’s Birthright Citizenship Restrictions 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.
